This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors, a hot new biotech start-up, and a new cosmetic drug.
In this video, health-care analyst David Williamson discusses a potential new solution to the double chin. Shares of Kythera (Nasdaq; KYTH) soared 25% on the news of a successful phase 3 trial for ATX-101, the sole drug in its pipeline.
Watch Market Checkup and find out more about the exciting cosmetic drug space, including a closer look at Botox maker Allergan (NYSE: AGN ) , and whether investors should jump aboard the Kythera bandwagon.
Stocks for a wealthy retirement
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
Follow David on Twitter: @MotleyDavid.